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were not part of the study, none were 
diagnosed with pandemic (H1N1) 
2009 during the study period. 
Our study began during the week 
in September 2009 in which the 
overall rate of incidence of pandemic 
(H1N1) 2009 in Spain reached 77.8 
cases per 100,000 inhabitants (4), a 
level that was above the threshold 
established for the previous inﬂ  uenza 
season, and ended during the week 
in which inﬂ  uenza activity fell below 
this threshold level (5). Therefore, the 
study spanned the full cycle of the 
epidemic. The national peak, with an 
overall rate of incidence of 372.7 cases 
per 100,000 inhabitants, occurred in 
week 10 of our study.
This series included 1 
asymptomatic carrier. We do not know 
if that ﬁ   nding could reﬂ  ect  a  false-
positive test or a low-virulence viral 
presence. 
Notably, among the population 
of health care workers taking part 
in the study, only 4 (11%) had been 
vaccinated against the novel form 
of the inﬂ  uenza A virus, and none of 
them had positive PCR results for 
pandemic (H1N1) 2009 virus. On the 
other hand, 5 (15%) of workers not 
vaccinated had a positive PCR result. 
This ﬁ  nding suggests that, despite the 
climate of uncertainty concerning the 
evolution of the inﬂ  uenza  outbreak, 
hospital workers had a greater fear 
of possible side effects of the vaccine 
than of the disease itself.
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Pandemic (H1N1) 
2009 and HIV 
Infection
To the Editor: In the United 
States during spring and fall of 2009, 
pandemic (H1N1) 2009 inﬂ  uenza A 
virus resulted in 2 major outbreaks 
of disease. Initial reports identiﬁ  ed 
immunosuppression, including HIV 
infection, as a risk factor for the 
development of severe inﬂ  uenza (1–
5). Subsequent reports did not conﬁ  rm 
this association, but the number of 
HIV-infected patients in these studies 
was small (6,7). We describe the 
clinical course of pandemic (H1N1) 
2009 in HIV-infected persons in a US 
hospital.
During 2009, 23 cases of 
laboratory-conﬁ  rmed  pandemic 
(H1N1) 2009 in HIV-infected persons 
were identiﬁ  ed at Harborview Medical 
Center (Seattle, WA, USA) by 
querying the University of Washington 
HIV Information System (a database 
that enables complete capture of all 
HIV testing results at Harborview 
Medical Center) and by querying 
the Harborview Infection Control 
Registry for inﬂ  uenza subtype H1N1 
infections. Most cases occurred during 
October and November. Baseline 
patient characteristics are noted in the 
Table. Most patients who sought care 
had fever and cough; median duration 
of symptoms before seeking care was 
4 days. Overall mortality rate for the 
entire cohort was 8.7%.
Of the 23 patients, only 2 were 
not treated for inﬂ   uenza; each had 
mild signs and symptoms and neither 
required hospital admission. Each of 
the remaining 13 outpatients received 
a 5-day course of treatment with 
oseltamivir. The 8 patients who required 
hospitalization received therapy for a 
median of 6 (range 1–22) days. 
Overall mortality rate among 
HIV-infected patients hospitalized 
for pandemic (H1N1) 2009 infection 
was 25% (2 of 8 patients). The 2 
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Table. Baseline characteristics for HIV-infected patients with pandemic (H1N1) 2009, Seattle, Washington, USA, 2009* 
Patient characteristics 
All patients,  
n = 23
Inpatients,
n = 8 
Outpatients,
n = 15  p value†
Demographics 
    Male sex  19 (83)  5 (63)  14 (93)  0.1
    Median age, y (range)  43 (22–72)  46 (34–72)  42 (22–64)  0.5
    Race/ethnicity  1.0
        White  14 (61)  5 (63)  9 (60) 
        Black  5 (22)  2 (25)  3 (20) 
        Hispanic   4 (17)  0 4 (27)  1.0
        Other/refused to answer  4 (17)  1 (13)  3 (20) 
History 
  Received 2009–10 seasonal influenza vaccine before illness  14 (61)  6 (75)  8 (53)  0.1
  Ever smoked  15 (65)  7 (88)  8 (53)  0.2
HIV-associated factors 
  CD4 count, cells/μL, median (range)  308 (32–1,024)  147 (32–1,024)  438 (119–833)  0.06
  Undetectable HIV-1 RNA  19 (83)  6 (75)  13 (87)  0.6
  Receiving antiretroviral therapy  21 (91)  8 (100)  13 (87)  0.5
Predisposing risk factors  15 (65)  6 (75)  9 (60)  0.5
    Prior lung disease  8 (35)  5 (63)  3 (20)  0.07
    Cardiovascular disease  4 (17)  3 (38)  1 (6.7)  0.1
    Obesity, body mass index >30  4 (17)  1 (13)  3 (20)  1.0
    Neutropenia  3 (13)  2 (25)  1 (6.7)  0.3
    Receiving immunosuppressive agent  3 (13)  3 (38)  0 0.03
    Malignancy  4 (17)  2 (25)  2 (13)  0.6
    Diabetes  2 (8.7)  0 2 (13)  0.5
Signs and symptoms  
    Fever  18 (78)  7 (88)  11 (73)  0.6
    Fatigue  5 (22)  2 (25)  3 (20)  1.0
    Malaise  11 (48)  7 (88)  4 (27)  0.009 
    Myalgia  10 (43)  3 (38)  7 (47)  1.0
    Sore throat  5 (22)  2 (25)  3 (20)  1.0
    Cough  21 (91)  8 (100)  13 (87)  0.5
    Dyspnea  8 (35)  4 (50)  4 (27)  0.4
    Nausea/vomiting  10 (43)  2 (25)  8 (53)  0.4
    Median duration of symptoms before seeking care, d (range)  4 (0–30)  4.5 (0–10)  3 (1–30)  0.6
Physical examination findings 
    Median temperature, qC (range)  38.0 (35.7–40.2)  39.1 (37.3–40.2)  37.7 (35.7–38.5)  0.001 
    Median heart rate, beats/min (range)  96 (69–129)  109 (80–127)  94 (69–129)  0.1
    Mean arterial blood pressure, mm Hg (range)  94 (66–116)  89 (66–98)  97 (75–116)  0.05
    Median respiratory rate, breaths/min (range)  20 (14–40)  22 (18–40)  19 (14–36)  0.04
    Abnormal lung sounds  11 (48)  8 (100)  3 (23)  0.001 
Laboratory findings 
    Leukocyte count, cells u 10
9/L (range)  4.53 (0.53–10.8)  3.2 (0.53–10.8)  5.4 (2.8–9.4)  0.4
    Leukopenia, <5,000 cells/μL  9 (39)  5 (63)  4 (40)  0.6
Chest radiograph findings, new infiltrate   6 (26)  5 (63)  1 (13)  0.1
Care received 
  Antiviral treatment for influenza  21 (91)  8 (100)  13 (87)  0.5
  Intensive care unit admission  3 (13)  3 (38)  NA
  Mechanical ventilation  2 (8.7)  2 (25)  NA
    Vasopressors  2 (8.7)  2 (25)  NA
Outcomes 
  Secondary pneumonia  3 (13)  3 (38)  0 0.03
  Thrombotic complications  1 (4.6)  1 (13)  0 0.4
  Died  2 (8.7)  2 (25)  0 0.1
*Values are no. (%) patients except as indicated. Among the 15 outpatients, 13 had a lung examination documented, 10 had a leukocyte count 
performed, and 8 had a chest radiograph taken. NA, not applicable. 
†For comparison of characteristics between inpatients and outpatients.  LETTERS
inpatients who died had each received 
>14 days of therapy with oseltamivir. 
Three inpatients were admitted to the 
intensive care unit (ICU); of these, 
2 had hypoxemic respiratory failure 
and bilateral inﬁ   ltrates at the time 
of admission and a later diagnosis of 
acute respiratory distress syndrome, 
and 1 was hospitalized with fever 
and hemodynamic instability. Each 
patient with acute respiratory distress 
syndrome subsequently died; 1 had 
methicillin-resistant  Staphylococcus 
aureus pneumonia at the time of 
admission, and 1 had severe hypoxemic 
respiratory failure requiring the 
use of rescue therapies (e.g., prone 
positioning and inhaled nitric oxide) 
and later treatment for ventilator-
associated pneumonia. Of the 2 
patients who died, 1 had concurrent 
conditions, including preexisting 
interstitial lung disease (believed to be 
associated with crack cocaine use) and 
a low CD4 cell count of 127 cells/μL, 
and 1 had a preserved CD4 cell count 
>1,000 cells/μL, but 8 days passed 
before anti-inﬂ   uenza therapy was 
started, and thrombotic complications 
developed before death. The lengths 
of ICU stay for the patients who died 
were 13 and 29 days.
Our  ﬁ   ndings are similar to 
those reported by others, suggesting 
that HIV infection alone does not 
appear to be a risk factor for severe 
pandemic (H1N1) 2009, provided 
that patients are not severely 
immunocompromised, do not have 
other risk factors associated with 
poor outcomes, and are treated 
for inﬂ   uenza soon after signs and 
symptoms develop (6–9). Most of 
the 23 patients described here had 
mild disease and were treated as 
outpatients. Only 3 required ICU 
admission, and 2 of these died. 
Although the mortality rate reported 
here is higher than that reported in 
other studies, our sample size was 
relatively small, and the patients who 
died had additional risk factors for 
poor outcomes.
Our study has several limitations. 
It is a retrospective study, and HIV-
infected patients at Harborview 
Medical Center were not all 
prospectively tested for pandemic 
(H1N1) 2009. Most pandemic 
(H1N1) 2009 virus was detected by 
reverse transcription PCR of nasal 
swab specimens; this testing was 
only available after October 2009, 
during the second wave of inﬂ  uenza. 
Infections occurring during the spring 
were diagnosed by insensitive testing 
with ﬂ  uorescent antibody and culture, 
diagnosed by clinical criteria alone 
and not included in this analysis, or 
missed altogether.
Because of differences in 
pandemic (H1N1) 2009 virus testing, 
we were unable to compare the 
incidence of pandemic (H1N1) 2009 
virus infection and outcomes between 
HIV-infected and HIV-uninfected 
patients. A total of 189 persons 
received a diagnosis of pandemic 
(H1N1) 2009 at Harborview 
Medical Center in 2009, and 79 were 
hospitalized. A total of 8 (10%) of 79 
patients with pandemic (H1N1) 2009 
died, including the 2 HIV-infected 
patients reported here. However, 
during the peak of the epidemic, many 
HIV-infected outpatients, who were 
receiving antiretroviral therapy and 
had preserved CD4 cell counts, were 
advised to remain at home if they had 
mild inﬂ  uenza-like symptoms and were 
therefore not tested for inﬂ  uenza. This 
circumstance could have produced a 
bias toward diagnosing and reporting 
only more severe disease. Outpatients 
who had inﬂ  uenza-like  symptoms 
were tested and treated empirically 
pending test results. Our case series of 
HIV-infected patients with pandemic 
(H1N1) 2009 at a single institution in 
the United States  suggests that HIV 
itself does not appear to be as major 
a risk factor for severe disease as are 
other previously reported concurrent 
conditions, delays in treatment, and 
development of secondary bacterial 
pneumonia.
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Swine Inﬂ  uenza 
Virus A (H3N2) 
Infection in Human, 
Kansas, USA, 2009
To the Editor: Triple-reassortant 
swine inﬂ  uenza viruses (SIVs), which 
contain genes from human, swine, 
and avian inﬂ   uenza A viruses, have 
been enzootic among swine herds in 
the United States since the late 1990s 
(1). Although uncommon, occasional 
transmission of triple-reassortant 
SIVs from swine to humans has 
occurred (2–4). Before April 2009, 
only limited, nonsustained human-
to-human transmission of SIVs had 
been reported (5–7). Although an 
animal source for pandemic (H1N1) 
2009 virus has yet to be identiﬁ  ed, 
the pandemic strain resulted from the 
reassortment of 2 different lineages of 
SIV (8).
On July 28, 2009, a 12-year-
old Kansas boy sought treatment for 
fever, cough, and sore throat. Results 
of an inﬂ  uenza rapid antigen test were 
positive, and a specimen was sent to 
the Kansas Department of Health and 
Environment for further testing. Real-
time reverse transcription PCR (rRT-
PCR) testing determined the virus 
contained the surface hemagglutinin 
(HA) gene of inﬂ  uenza A (H3) and the 
internal nucleoprotein gene common 
to all triple-reassortant SIVs (9). The 
specimen was sent to the Centers 
for Disease Control and Prevention 
(Atlanta, GA, USA) on August 3 and 
identiﬁ   ed as swine-origin inﬂ  uenza 
virus A (H3N2) by rRT-PCR and 
sequence analysis.
The patient reported that during 
July 23–25, 2009, he touched healthy-
appearing swine multiple times 
while attending a county fair. The 
boy received a standard treatment 
course of oseltamivir and recovered 
completely. None of his 3 household 
contacts attended the fair, and none 
reported signs or symptoms of illness 
in the weeks afterward.
The Kansas Department of Health 
and Environment and the local health 
department collaborated with the 
county extension ofﬁ   ce to identify 
and interview swine exhibitors at the 
county fair, focusing on inﬂ  uenza 
symptoms among exhibitors and 
household contacts during the week 
before and after the fair. Twenty-seven 
(79%) of 34 exhibitors participated 
in the survey; none reported signs or 
symptoms of inﬂ  uenza-like  illness, 
deﬁ  ned as fever (temperature >100°F) 
accompanied by either cough or sore 
throat. Two household contacts of 
separate exhibitors each reported a 
low-grade fever (<100°F) and sore 
throat in the week after the fair. Both 
touched swine while attending the 
fair. Both visited a physician’s ofﬁ  ce; 
neither was tested for inﬂ  uenza; and 
symptoms of both resolved without 
treatment. The veterinarian overseeing 
the swine barn reported no signs of 
respiratory illness among the swine 
during the fair. Most swine exhibited 
were slaughtered at the fair’s 
conclusion.
On August 7, the Kansas Animal 
Health Department collected nasal 
swab specimens and blood samples 
from 13 swine belonging to 7 
exhibitors. All samples were delivered 
to the Kansas State Veterinary 
Diagnostic Laboratory for analysis 
by inﬂ   uenza matrix rRT-PCR and 
virus isolation on nasal swab samples 
and hemagglutination inhibition (HI) 
assays against classical swine inﬂ  uenza 
virus (H1N1) (A/swine/Iowa/73) 
and the prototype swine inﬂ  uenza 
virus (H3N2) (A/swine/Texas/98) 
on serum samples. In addition, the 
inﬂ  uenza virus (H3N2) “county fair” 
isolate, A/Kansas/13/2009 (H3N2), 
was sent from the Centers for Disease 
Control and Prevention, ampliﬁ  ed, 
and used to develop a second HI 
assay that included the original swine 
serum samples as well as paired 
convalescent-phase samples from 3 of 
the swine (Table). 
Inﬂ   uenza matrix RT-PCR and 
virus isolation on nasal swab samples 
were negative. HI assays demonstrated 
little or no antibody against the 
inﬂ  uenza (H1N1) indicator virus and 
low-level antibody reaction against 
the prototype swine inﬂ  uenza  virus 
(H3N2). However, HI titers against the 
“county fair” inﬂ  uenza virus (H3N2) 
showed consistently elevated titers, 
which suggested that the animals 
might have been exposed to the virus 
2 weeks earlier, during the time of 
the fair. The swine may have cleared 
the virus by the time the nasal swabs 
were collected, but without positive 
RT-PCR or virus isolation results, the 
situation remain inconclusive.
We compared the HA gene 
segment of A/Kansas/13/2009 (H3N2) 
with recent animal and human 
inﬂ   uenza (H3N2) viruses by using 
the neighbor-joining method, and it 
clustered with the HA from recent 
triple-reassortant SIV (H3N2) isolates 
(online Appendix Figure, www.
cdc.gov/EID/content/17/6/1143-
appF.htm) (10). A/Kansas/13/2009 
(H3N2) shares >97% nucleotide 
identity with 2 swine viruses reported 
to have caused human infections, 
A/Ontario/RV1273/2005 and A/
Ontario/1252/2007, and >90% 
nucleotide identity with currently 
circulating seasonal (H3N2) 
viruses, such as A/Perth/16/2009. 
Sequence analysis for the remaining 
7 gene segments conﬁ  rmed  A/
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